- Patent Title: Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypryridin-2-YL)benzoic acid
-
Application No.: US16765350Application Date: 2018-11-14
-
Publication No.: US11325909B2Publication Date: 2022-05-10
- Inventor: Dilinie Fernando , Shawn Marie LaCasse , Kristin Elizabeth Price Wiglesworth
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent Richard V. Zanzalari
- International Application: PCT/IB2018/058966 WO 20181114
- International Announcement: WO2019/102311 WO 20190531
- Main IPC: C07D471/10
- IPC: C07D471/10
![Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypryridin-2-YL)benzoic acid](/abs-image/US/2022/05/10/US11325909B2/abs.jpg.150x150.jpg)
Abstract:
The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmaceutical compositions, dosage forms, and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.
Information query